BTSG — BrightSpring Health Services, Inc. Common Stock

Summary of BrightSpring Health Services, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Performance: Revenue increased by approximately 29% year-over-year, with adjusted EBITDA growing by 41%.
• Full Year 2025: Total revenue reached $12.9 billion (up 28% YoY), with Pharmacy Solutions revenue at $11.4 billion (up 31%) and Provider Services revenue at $1.5 billion (up 11%). Adjusted EBITDA for the year was $618 million, reflecting a 34% increase.
• Cash Flow: Generated $490 million in cash flow from operations for the year, with a leverage ratio of 2.99x, down from 4.16x in 2024.
• Adjusted EPS: $0.33 for Q4 and $1.00 for the full year.

2. Strategic Updates and Business Highlights

• Divestiture: Announced the divestiture of the Community Living business, expected to close by the end of Q1 2026, generating approximately $715 million in net cash proceeds, primarily for debt reduction.
• Acquisitions: Completed the acquisition of Amedisys, adding 107 branches for $239 million, expected to contribute $30 million to adjusted EBITDA in 2026.
• Operational Improvements: Continued focus on efficiency through technology investments and procurement initiatives, resulting in improved margins across segments.
• Patient Satisfaction: Maintained high satisfaction scores across services, with home health branches achieving over 91% rated four stars or greater.

3. Forward Guidance and Outlook

• 2026 Guidance: Total revenue expected to grow by approximately 14% YoY, with a range of $14.45 billion to $15.0 billion. Adjusted EBITDA is projected to grow by 23% to 28%, with a range of $760 million to $790 million.
• Segment Contributions: Pharmacy Solutions revenue is expected between $12.6 billion and $13.1 billion, while Provider Services revenue is anticipated to be between $1.85 billion and $1.9 billion.

4. Bad News, Challenges, or Points of Concern

• Headwinds: Anticipated revenue headwinds of approximately $400 million in the pharmacy segment due to IRA impacts and brand-to-generic conversions.
• Customer Losses: Experienced a decline in home and community pharmacy revenue due to the bankruptcy of a large customer and exit from uneconomic accounts.
• Integration Risks: Potential integration challenges with the Amedisys acquisition, including technology investments and cultural assimilation.

5. Notable Q&A Insights

• Market Outlook: Management expressed optimism about the home health market, projecting flat rates but potential for future increases due to constructive industry discussions.
• Operational Efficiency: Emphasis on ongoing investments in AI and technology to enhance operational efficiencies and drive growth across segments.
• Segment Margins: Expected broad-based margin expansion across segments, driven by operational improvements and favorable product mix.
• Specialty Pharmacy Strategy: Continued focus on expanding the specialty pharmacy business, with plans for 16 to 20 new limited distribution drug launches over the next 12 to 18 months.

Overall, BrightSpring Health Services demonstrated strong financial performance in 2025, with strategic initiatives aimed at enhancing operational efficiency and expanding service offerings, despite facing some headwinds and challenges in the upcoming year.